

Cytotoxic and antimicrobial drimane meroterpenoids from a fungus of the *Stictidaceae* (Ostropales, Ascomycota)

By: Laura Flores-Bocanegra, Mario Augustinovic, [Huzefa A. Raja](#), Steven J. Kurina, Amanda C. Maldonado, Joanna E. Burdette, Joseph O. Falkinham, [Cedric J. Pearce](#), and [Nicholas H. Oberlies](#)

Laura Flores-Bocanegra, Mario Augustinovic, Huzefa A. Raja, Steven J. Kurina, Amanda C. Maldonado, Joanna E. Burdette, Joseph O. Falkinham, Cedric J. Pearce, Nicholas H. Oberlies. Cytotoxic and antimicrobial drimane meroterpenoids from a fungus of the *Stictidaceae* (Ostropales, Ascomycota). *Tetrahedron Letters*. Volume 68, 30 March 2021, Article number 152896. DOI: 10.1016/j.tetlet.2021.152896




This work is licensed under a [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License](#).

Reprinted with permission. This version of the document is not the version of record.

Abstract:

As part of our ongoing research on bioactive fungal metabolites, two new metabolites were isolated from a fungus of the *Stictidaceae* (strain MSX62440), dasyscyphins F and G (**1** and **3**), along with the known dasyscyphin C (**2**). Compound **1** was characterized by HRMS and 1D and 2D NMR data, and its absolute configuration established by ECD spectroscopy. A structural revision of dasyscyphin C (**2**) was based on NMR data and verified by ECD calculations. Compound **3** was previously reported as a synthetic product, and its identity confirmed by comparison with NMR data in the literature, and its absolute configuration was established by ECD spectroscopy. Compounds **1** and **2** showed moderate cytotoxicity and antimicrobial activity.



Keywords: Meroterpenoids | Dasyscyphins | *Stictidaceae* sp. | Cytotoxic | Antimicrobial

Article:

As part of ongoing studies in pursuit of potential drug leads from the Mycosynthetix library of filamentous fungi [1], [2], [3], the organic extract from a fungus of the *Stictidaceae* (strain MSX62440, Fig. S1) displayed moderate activity against the human cancer cell lines MDA-MB-435 (melanoma), MDA-MB-231 (breast) and OVCAR3 (ovarian) (~65% inhibition of cell growth when tested at 20 $\mu\text{g/mL}$). Bioactivity-directed fractionation using flash chromatography followed by HPLC resulted in the isolation of two natural products, dasyscyphin F and G (**1** and **3**), along with the known dasyscyphin C (**2**) [4] (Fig. 1).




Fig. 1. Compounds isolated from a fungus of the *Stictidaceae* (strain MSX62440).

Compound **1** [5] was isolated as an optically active powder ($[\alpha]_{\text{D}20} = +27$, $c = 0.1$, CH_3OH). The molecular formula was established as $\text{C}_{22}\text{H}_{30}\text{O}_3$ by HRESIMS (Fig. S2), indicating an index of hydrogen deficiency of 8. Analysis of the ^1H , ^{13}C , and HSQC NMR data (Fig. S3, S4, and Table 1) indicated 22 carbons, consisting of four methyls ($\delta_{\text{H}}/\delta_{\text{C}}$ 0.49/15.7, 0.80/21.9, 1.25/30.4, and 0.89/33.4), six methylenes ($\delta_{\text{H}}/\delta_{\text{C}}$ 0.92 and 1.68/41.3, 1.39 and 1.49/18.5, 1.15 and 1.41/42.1, 1.63 and 1.32/19.6, 1.75 and 2.82/32.8, and 2.73 and 2.90/29.4), three methines ($\delta_{\text{H}}/\delta_{\text{C}}$ 0.98/51.9, 1.75/62.0, and 6.75/116.8), one aldehyde ($\delta_{\text{H}}/\delta_{\text{C}}$ 9.72/195.9), and eight non-protonated carbons (δ_{C} 33.4, 37.3, 48.5, 120.1, 140.1, 142.0, 144.6, and 153.0). These data were similar to those reported for dasyscyphin B [4], where the main difference was the lack of a methoxymethyl group attached to the aromatic ring at position C-15 (i.e., $\delta_{\text{H}-22}/\delta_{\text{C}-22}$ 4.60/74.3 and $\delta_{\text{H}}/\delta_{\text{C}}$ 3.42/58.0 as reported [4]), which was replaced by an aldehyde ($\delta_{\text{H}}/\delta_{\text{C}}$ 9.72/195.9), whose position was verified by the HMBC correlations between H-22 with C-14, C-15, and C-16 (Fig. 2). The skeleton for the tricyclic-ring system for the sesquiterpene portion of **1** was confirmed by analysis of the COSY and HMBC experiments (Fig. 2). Specifically, the COSY spectrum (Fig. S5) indicated three isolated spin systems H₂-1/H₂-2/H₂-3, H-5/H₂-6/H₂-7, and H-9/H₂-11 (Fig. 2); key HMBC correlations were used to connect these, particularly H-1 with C-9, H-3 with C-5, H-7 with C-9, H-11 with C-17 and C-12, and H-7 with C-17 (Fig. S6). The relative configuration was assigned through NOESY correlations (Fig. 2 and S7) between H₃-21/H₂-6/H₂-11, H₃-18/H-5/H-9, and H-5/H₃-19; the relative configuration was identical to that of other dasyscyphin analogues [4], [6]. The absolute configuration of **1** was determined by comparison of the experimental and calculated ECD spectra. TDDFT calculations were used to predict the ECD spectrum for the proposed relative configuration, using the B3LYP/G-31 + G(d,p) level of theory, and the experimental data matched the calculated spectrum for the 5*S*,8*S*,9*R*,10*S* configuration (Fig. 3). Compound **1** was ascribed the trivial name dasyscyphin F.

Table 1. NMR data for compound **1** in CDCl₃ (400 and 100 MHz for ¹H and ¹³C, respectively).

position	δ_c	type	δ_H , mult (<i>J</i> in Hz)
1	41.3	CH ₂	1.68, m, 0.92, m
2	18.5	CH ₂	1.49, m, 1.39, m
3	42.1	CH ₂	1.15, td (14.2, 13.5, 4.4) 1.41, m
4	33.4	C	
5	51.9	CH	0.98 dd (11.4, 4.4)
6	19.6	CH ₂	1.63, 1.32m
7	32.8	CH ₂	2.82 dt (13.8, 5.5) 1.75m
8	48.5	C	
9	62.0	CH	1.75, m
10	37.3	C	
11	29.4	CH ₂	2.90, dd (17.6, 7.9) 2.73, d (17.5)
12	142.0	C	
13	153.0	C	
14	116.8	CH	6.75, s
15	120.1	C	
16	144.6	C	
17	140.1	C	
18	30.4	CH ₃	1.25, s
19	33.4	CH ₃	0.89, s
20	21.9	CH ₃	0.80, s
21	15.7	CH ₃	0.49, s
22	195.9	CH	9.72, s
16-OH			10.82, s




Fig. 2. Key COSY (bold lines), HMBC (solid arrows) and NOESY (dashed arrows) correlations of **1**.




Fig. 3. Comparison of the ECD spectra of **1** in CH₃OH. Experimental spectrum recorded at 0.2 mg/mL (solid line), and calculated spectra for the two possible enantiomers (dotted and dashed lines).

Compound **3** [15] was isolated as an optically active powder ($[\alpha]_{D20} = +13$, $c = 0.1$, CH₃OH). The molecular formula was established as C₂₃H₃₂O₃ based on the protonated molecule observed in the HRESIMS spectrum. Analysis of the ¹H, ¹³C and HSQC NMR spectra (Fig. S13) supported the presence of 23 carbons, including four methyl groups (δ_H/δ_C 0.70/16.0, 0.84/21.5, 0.85/32.9, and 1.25/29.8), seven methylene groups (δ_H/δ_C 0.90 and 1.59/41.8, 1.13 and 1.41/42.3, 1.34 and 1.66/19.0, 1.37 and 1.37 and 1.50/18.5, 1.80 and 2.17/30.8, 2.60 and 2.73/29.4, and 4.27/68.1), three methine groups (δ_H/δ_C 1.00/49.9, 1.64/59.9, and 6.63/131.0), one methoxy (δ_H/δ_C 3.44/59.3), and eight non-protonated carbons, including two ketones (δ_C 33.5, 36.9, 49.6, 146.2, 147.5, 153.6, 186.1, and 187.3); these data were in agreement with the structure of an intermediate in the synthesis of dasyscyphin B [16] (Table S2). The reported relative configuration for **3** is the same as compound **2**, and its ECD spectrum showed the same Cotton effects observed in **2** (Fig. S16). This evidence, along with biogenetic considerations, suggests the absolute configuration for **3** as 5*S*,8*S*,9*R*,10*S*. This is the first-time compound **3** has been isolated as a natural product, and it was ascribed the trivial name dasyscyphin G.

Compounds **1–3** were tested against the human cancer cells lines MDA-MB-435 (melanoma), MDA-MB-231 (breast) and OVCAR3 (ovarian). The results showed that **1** and **2** were moderately active with IC₅₀ values ranging from 4 to 16 μ M against the three cell lines while compound **3** was effectively inactive (Table 2). These data were consistent with the literature on related dasyscyphin analogues, where cytotoxic activities ranged from 1 to 8 μ M [17].

Table 2. Cytotoxic activity of compounds **1–3** against MDA-MB-435 (melanoma), MDA-MB-231 (breast) and OVCAR3 (ovarian) cancer cell lines.

	IC ₅₀ values (μ M)		
	MDA-MB-435	MDA-MB-231	OVCAR3
1	4.1	8.2	16.2
2	14.1	12.2	10.4
3	19.7	>25	>25
taxol	0.007	0.002	0.003

Table 3. Antimicrobial activities of compounds **1** and **2** against a suite of microorganisms.

Microorganisms	Minimal inhibitory concentration (μ g/mL)		
	1	2	Erythromycin
<i>E. coli</i>	>125	>125	8
<i>S. aureus</i>	>125	>125	0.125
MRSA	63	16	>25
<i>P. aeruginosa</i>	125	63	32
<i>M. smegmatis</i>	>125	>125	125
<i>B. subtilis</i>	>125	>125	>125
<i>B. anthracis</i>	31	2	0.25
<i>S. cerevisiae</i>	>125	>125	>125
<i>C. albicans</i>	>125	>125	>125
<i>A. niger</i>	>125	>125	>125

Since the dasyscyphins have been studied as antifungal and antibacterial agents [6], [17] we evaluated the antimicrobial activity of **1** and **2** against *Escherichia coli*, *Staphylococcus aureus*,

Methicillin-resistant *Staphylococcus aureus* (MRSA), *Pseudomonas aeruginosa*, *Mycobacterium smegmatis*, *Bacillus subtilis*, *Bacillus anthracis*, *Saccharomyces cerevisiae*, *Candida albicans* and *Aspergillus niger*. Compounds **1** and **2** (Table 3) inhibited the growth of *P. aeruginosa*, Methicillin-resistant *Staphylococcus aureus* (MRSA), and *B. anthracis*, and of those, the MIC of **2** against *B. anthracis* (MIC value of 2 µg/mL) was the most potent.

In conclusion, we report the isolation and elucidation of three drimane meroterpenoids (**1–3**) from a fungus of the *Stictidaceae*. This includes the description of two natural products, dasyscyphin F (**1**) and G (**3**), and a structural revision of dasyscyphin C (**2**), demonstrating that it has a 2-cyclohexene-1,4-dione ring, instead of a 2-cyclohexene-1,2-dione, as noted from analysis of both NMR chemical shifts and ECD calculated spectra. The structural characterizations of **1–3** were established using a combination of conventional spectrometric (HRESIMS) and spectroscopic (NMR) techniques, while their absolute configurations were determined by analysis of measured vs calculated ECD spectra. Moreover, we report that dasyscyphin F and C (**1** and **2**) had moderate cytotoxic activity, and the potent MIC of compound **2** vs *B. anthracis* merits further study.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This research was supported by P01 CA125066 from the National Cancer Institute. We thank Tyler Graf from UNCG for helpful suggestions.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.tetlet.2021.152896>.

References

- [1] T. El-Elimat, X. Zhang, D. Jarjoura, F.J. Moy, J. Orjala, A.D. Kinghorn, C.J. Pearce, N.H. Oberlies, *ACS Med. Chem. Lett.* 3 (2012) 645–649.
- [2] T. El-Elimat, H.A. Raja, S. Ayers, S.J. Kurina, J.E. Burdette, Z. Mattes, R. Sabatelle, J.W. Bacon, A.H. Colby, M.W. Grinstaff, C.J. Pearce, N.H. Oberlies, *Org. Lett.* 21 (2019) 529–534.
- [3] A.D. Kinghorn, E.J.C. De Blanco, D.M. Lucas, H.L. Rakotondraibe, J. Orjala, D.D. Soejarto, N.H. Oberlies, C.J. Pearce, M.C. Wani, B.R. Stockwell, *Anticancer Res.* 36 (2016) 5623–5637.
- [4] V. Rojas de la Parra, V. Mierau, T. Anke, O. Sterner, *Tetrahedron* 62 (2006) 1828–1832.

- [5] Dasyscyphin F (1): Yellow powder; λ_{max} (c = 0.1, CH₃OH); UV (CH₃OH) λ_{max} (log ϵ) 254 (3.63); ¹H NMR (CDCl₃, 400 MHz) and ¹³C NMR (CDCl₃, 100 MHz) see Table 1 and Fig. S2; HRESIMS m/z 341.2125 [M-H]⁻ (calcd. for C₂₂H₂₉O₃, m/z 341.2122, 0.8 ppm).
- [6] J.C. Liermann, H. Kolshorn, H. Anke, E. Thines, T. Opatz, *J. Nat. Prod.* 71 (2008) 1654–1656.
- [7] Dasyscyphin C (2): orange powder = -28 (c = 0.1, CH₃OH); UV (CH₃OH) λ_{max} (log ϵ) 289 (2.32); ¹H NMR (CDCl₃, 400 MHz) and ¹³C NMR (CDCl₃, 100 MHz), see Table S1 and Fig. S9; HRESIMS m/z 505.2780 [M-H]⁺ (calcd. for C₂₈H₄₁O₈, 505.2795, 3.2 ppm).
- [8] G. Zhang, H. Ma, S. Hu, H. Xu, B. Yang, Q. Yang, Y. Xue, L. Cheng, J. Jiang, J. Zhang, F. Wang, Y. Zhang, *Fitoterapia* 110 (2016) 59–65.
- [9] K. Ma, L. Li, L. Bao, L. He, C. Sun, B. Zhou, S. Si, H. Liu, *Tetrahedron* 71 (2015) 1808–1814.
- [10] Y. Yang, Y. Zhang, D. Liu, M. Li-Weber, B. Shao, W. Lin, *Fitoterapia* 103 (2015) 277–282.
- [11] Y. Komoda, H. Nakamura, S. Ishihara, M. Uchida, H. Kohda, K. Yamasaki, *Chem. Pharm. Bull.* 33 (1985) 4829–4835.
- [12] P. Georgantea, E. Ioannou, E. Evain-Bana, D. Bagrel, N. Martinet, C. Vagias, V. Roussis, *Tetrahedron* 72 (2016) 3262–3269.
- [13] S.-T. Fang, J.-K. Liu, B. Li, *Steroids* 77 (2012) 36–44.
- [14] J.-Q. Liu, Y.-F. Yang, C.-F. Wang, Y. Li, M.-H. Qiu, *Tetrahedron* 68 (2012) 972–976.
- [15] Dasyscyphin G (3): yellow oil; λ_{max} (c = 0.1, CH₃OH); UV (CH₃OH) λ_{max} (log ϵ) 289 (2.79); ¹H NMR (DMSO-d₆, 400 MHz) and ¹³C NMR (DMSO-d₆, 100 MHz), see Table S2 and Fig. S13; HRESIMS m/z 357.2416 [M+H]⁺ (calcd. for C₂₃H₃₃O₃, 357.2424, 2.6 ppm)
- [16] A. Akhaouzan, A. Fernandez, A.I. Mansour, E. Alvarez, A. Haidoeur, R. Alvarez-Manzaneda, R. Chahboun, E. Alvarez-Manzaneda, *Org. Biomol. Chem.* 11 (2013) 6176–6185.
- [17] V. Mierau, V. Rojas De La Parra, O. Sterner, T. Anke, *J. Antibiot.* 59 (2006) 53–56.